This study is looking at bimekizumab, a drug that works by targeting a specific pathway in the body called MEK. Researchers want to see if giving bimekizumab in different ways (intravenously, meaning into a vein, or subcutaneously, meaning under the skin) is safe and moves through the body similarly over time. This study is for adults aged 18 and older who have active psoriatic arthritis (a type of arthritis affecting some people with psoriasis) or axial spondyloarthritis (a type of arthritis that mainly affects the spine). You can join if you haven't taken certain biologic medications before, or if you stopped them a while ago. The main goal is to measure how much bimekizumab is in your body at Week 16. The study plans to enroll 392 participants, but its current status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 392 participants.

What's involved

Participants will receive bimekizumab at pre-specified time points. The primary endpoint is measured at Week 16.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 16, but longer follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.